HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* ...

Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...

Nevro yesterday announced that the FDA has granted approval for a study evaluating its high-frequency spinal cord stimulation system for the treatment of chronic pain. The device company’s Senza ...

Backed by the likes of Johnson & Johnson and Mayo Clinic, Nevro Corp. has raised $58 million to prepare for a hoped-for U.S. launch of its spinal cord stimulator for chronic pain, according to a ...